Published in Lupus on March 01, 2008
Mucosal-dominant pemphigus vulgaris in a captopril-taking woman with angioedema. An Bras Dermatol (2015) 0.75
Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy. Osteoporos Int (2014) 5.05
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet (2001) 2.75
The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet (2009) 1.73
Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol (2008) 1.54
Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol (2004) 1.50
STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis (2008) 1.42
[Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions]. Rev Clin Esp (2004) 1.40
Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol (2011) 1.29
Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun (2006) 1.22
Cellular adhesion mediated by factor J, a complement inhibitor. Evidence for nucleolin involvement. J Biol Chem (1998) 1.21
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis (2009) 1.06
Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. Arch Neurol (2001) 1.06
Interleukin 12 (IL12B), interleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A) gene polymorphism in systemic lupus erythematosus. Rheumatology (Oxford) (2005) 1.03
Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis (2010) 1.02
Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol (2011) 0.99
A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann Rheum Dis (2008) 0.95
Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant (2009) 0.94
Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol (2007) 0.92
Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis. Genes Immun (2012) 0.92
Analysis of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus. Tissue Antigens (2007) 0.90
Complement component C7 deficiency in a Spanish family. Clin Exp Immunol (2003) 0.90
Ileitis terminalis in a patient with Henoch-Schönlein purpura. Dig Dis Sci (1999) 0.89
A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum (2012) 0.89
The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis (2008) 0.89
Evidence of an immediate hypersensitivity mechanism in systemic lupus erythematosus. Ann Rheum Dis (1980) 0.85
Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom (2010) 0.84
Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol (2006) 0.84
Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population. Lupus (2006) 0.83
No primary association of MICA polymorphism with systemic lupus erythematosus. Rheumatology (Oxford) (2006) 0.82
A novel nonsense mutation at Glu-631 in a Spanish family with complement component 7 deficiency. J Hum Genet (1999) 0.82
Association study of IRAK-M and SIGIRR genes with SLE in a large European-descent population. Lupus (2012) 0.81
A novel method for direct measurement of complement convertases activity in human serum. Clin Exp Immunol (2014) 0.81
No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus. Lupus (2009) 0.80
C3 nephritic factor determination. A comparison between two methods. J Immunol Methods (1987) 0.80
Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus. Clin Exp Rheumatol (2009) 0.80
Study of the role of functional variants of SLC22A4, RUNX1 and SUMO4 in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.79
Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods (2011) 0.79
Study of two polymorphisms of the MHC2TA gene with systemic lupus erythematosus. Rheumatology (Oxford) (2007) 0.79
Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. Medicine (Baltimore) (2015) 0.79
[Paniculitis, polyarthritis and pancreatitis]. Rev Clin Esp (2008) 0.78
Angioedema and transient acquired C1 inhibitor functional deficiency in HIV infection: case report. AIDS (2002) 0.78
C7 deficiency and meningococcal infection susceptibility in two spanish families. Scand J Immunol (2010) 0.78
Vitamin D deficiency in a cohort of patients with systemic lupus erythematous from the South of Spain. Lupus (2010) 0.78
Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol (2007) 0.77
Stress as a predictor of cognitive functioning in lupus. Lupus (2006) 0.77
Interaction of C3 nephritic factor (NEF) with erythrocyte membranes complement-independent binding to sheep and patients' erythrocytes. Mol Immunol (1991) 0.77
Internalization of factor J and cellular signalization after factor J-cell interaction. Biochem Biophys Res Commun (1999) 0.77
Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol (2008) 0.77
Determination of C3 nephritic factor activity by a microassay based on the peroxidase-like activity of the heme group. Clin Biochem (1990) 0.77
Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine. J Eur Acad Dermatol Venereol (2007) 0.76
Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Haemostasis (1997) 0.76
Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol (2009) 0.76
Autoantibodies in patients with IgA and IgG2 deficiencies. APMIS (1991) 0.76
Clinical Pattern and Acute and Long-term Management of Hereditary Angioedema Due to C1-Esterase Inhibitor Deficiency. J Investig Allergol Clin Immunol (2015) 0.76
Stroke prevention. Should we use perindopril? J Neurol (2003) 0.75
Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro. Immunology (1992) 0.75
Raynaud's phenomenon and pulmonary arterial hypertension. Lupus (2008) 0.75
Bilateral naevus of Ota in a pregnant white woman. Clin Exp Dermatol (2009) 0.75
Utility of HLA typing in the differential diagnosis of severe aphthosis and Behçet's disease. Dermatology (2000) 0.75
Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma. Curr Oncol (2010) 0.75
Incidence of selective IgG2 deficiency in patients with vasculitis. Clin Exp Immunol (1989) 0.75
Efalizumab for subacute cutaneous lupus: report of two different outcomes. Lupus (2009) 0.75
A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis. Clin Exp Rheumatol (2013) 0.75
[Deficiencies of C1 inhibitor: hereditary and acquired angioedema]. Rev Clin Esp (1996) 0.75
Factor J, an inhibitor of the classical and alternative complement pathway, does not inhibit esterolysis by factor D. Biochim Biophys Acta (1996) 0.75
Factor J, a human inhibitor of complement C1, is a cationic, highly glycosylated protein. Immunol Lett (1994) 0.75
[Childhood bullous pemphigoid]. An Pediatr (Barc) (2011) 0.75
Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab. Eur J Intern Med (2008) 0.75
Factor J, an inhibitor of the complement classical pathway: the quantitation by an ELISA inhibition assay in normal human serum. Clin Biochem (1994) 0.75
Intravascular lymphoma in a patient with systemic lupus erythematosus: a case report. Lupus (2007) 0.75
[Nevoid hyperkeratosis of the nipple and areola]. An Pediatr (Barc) (2006) 0.75
[Necrotizing systemic sarcoidosis with pulmonary and central nervous system involvement]. An Med Interna (2008) 0.75
[Experience with rituximab in the treatment of systemic erythematosus lupus]. Reumatol Clin (2008) 0.75
[Hair casts]. An Pediatr (Barc) (2006) 0.75
Agreement between Framingham-DORICA and SCORE scales in estimation of cardiovascular risk in the patients suffering from metabolic syndrome in Granada (Spain). Ir J Med Sci (2011) 0.75
The inhibitory effect of factor J on the alternative complement pathway. J Biol Chem (1994) 0.75
[Twenty-nail dystrophy and lichen planus]. An Pediatr (Barc) (2007) 0.75
Cell surface molecules related to factor J in human lymphoid cells and cell lines. J Immunol (1995) 0.75
[Pemphigoid gestationis: therapeutic response to pre- and postpartum immunoglobulin therapy]. Actas Dermosifiliogr (2011) 0.75